Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,038 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Not listed Not applicable Interventional

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

NCT00436709
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, adjuvant therapy, immunoscintigraphy
Biological · Drug · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

NCT01828021
View directory record Official record
Conditions
Breast Cancer
Interventions
Margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Plantation, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

NCT01095848
View directory record Official record
Conditions
Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
Biological
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Buffalo, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Not applicable Interventional

Yoga Practice for Breast or Ovarian Cancer Patients

NCT02305498
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer
Interventions
Vigorous yoga practice, Restorative (gentle) yoga practice
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 30, 2026, 9:07 AM EDT
Active, not recruiting No phase listed Observational

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

NCT06663787
View directory record Official record
Conditions
Breast Cancer, Metastatic, HER2 + Breast Cancer
Interventions
Trastuzumab (Herceptin), SIgnatera
Drug · Diagnostic Test
Lead sponsor
Nagoya City University
Other
Eligibility
20 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Carlos, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 30, 2026, 9:07 AM EDT
Recruiting Phase 2 Interventional

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

NCT04434040
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
Interventions
Atezolizumab, Sacituzumab govitecan
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • New Lenox, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 30, 2026, 9:07 AM EDT
Completed No phase listed Observational

Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions

NCT01773850
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 2 Interventional

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

NCT05963984
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions
Samuraciclib, Fulvestrant
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Not applicable Interventional

Yoga Breathing for Fatigue in Patients Undergoing Chemotherapy

NCT00982748
View directory record Official record
Conditions
Breast Cancer
Interventions
Pranayama (Yoga Breathing) Techniques
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 1 Interventional

Visualization of the Effect of Acupuncture on Brain Serotonin in Breast Cancer Survivors

NCT01018108
View directory record Official record
Conditions
Breast Cancer
Interventions
Single Photon Emission Computed Tomography, Acupuncture Therapy, Questionnaire Administration, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 4 Interventional Results available

Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU

NCT01781299
View directory record Official record
Conditions
Breast Cancer, Mastectomy
Interventions
AlloDerm RTU, SurgiMend PRS
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 2 Interventional

A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

NCT00001498
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
methotrexate, leucovorin, 5-fluorouracil, cyclophosphamide, peripheral blood progenitor cell, paclitaxel, doxorubicin
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 30, 2026, 9:07 AM EDT
Withdrawn No phase listed Observational

Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging

NCT01277263
View directory record Official record
Conditions
Breast Cancer
Interventions
Diffuse Optical Spectroscopy Imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Costa Mesa, California • Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 30, 2026, 9:07 AM EDT
Completed No phase listed Observational

A Pilot Study of Working Women and Breast Cancer

NCT01914614
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Robin Vanderpool
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Not applicable Interventional

Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma

NCT03612648
View directory record Official record
Conditions
Breast Carcinoma, Breast Cancer
Interventions
Three Fraction Accelerated Partial Breast Irradiation, Partial mastectomy
Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

NCT02073487
View directory record Official record
Conditions
Breast Cancer
Interventions
T-DM1, Trastuzumab, Lapatinib, Abraxane, Paclitaxel, Pertuzumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 30, 2026, 9:07 AM EDT
Completed No phase listed Observational

Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer

NCT02366806
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 2 Interventional

S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

NCT00015938
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, docetaxel, vinorelbine
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
99
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

NCT02779855
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
Interventions
Talimogene laherparepvec, Paclitaxel
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 1 Interventional Results available

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

NCT01286987
View directory record Official record
Conditions
Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 2Phase 3 Interventional

Acupressure for Persistent Cancer Related Fatigue

NCT01281904
View directory record Official record
Conditions
Chronic Fatigue, Breast Cancer, Sleepiness
Interventions
Relaxation Acupressure, Stimulating Acupressure
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Sep 30, 2026, 9:07 AM EDT
Completed No phase listed Observational

Experience of Arab American Women With Breast Cancer: In-depth Interviews

NCT02710058
View directory record Official record
Conditions
Breast Cancer
Interventions
one-time qualitative assessment
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Sep 30, 2026, 9:07 AM EDT
Completed Phase 1Phase 2 Interventional

Analyzing the Composition of Tears to Identify Cancer

NCT00574678
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Benign Disease
Interventions
Tear collection
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 30, 2026, 9:07 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Biennial CEM in Women With a Personal History of Breast Cancer

NCT06105749
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Cancer Female, Neoplasms
Interventions
contrast-enhanced mammography
Device
Lead sponsor
Wendie Berg
Other
Eligibility
30 Years to 79 Years · Female only
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
6
States / cities
Bethel Park, Pennsylvania • Cranberry Township, Pennsylvania • Monroeville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 30, 2026, 9:07 AM EDT